Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1979913 | 0.86 | ALDH1A1 (0.56) | ALDH1A1TSHRTDP1MAPTLMNA | |
| SCHEMBL29739542 | 0.86 | ALDH1A1 (0.56) | ALDH1A1TSHRTDP1MAPTLMNA | |
| SCHEMBL5511217 | 0.85 | HTT (0.58) | ALDH1A1TSHRTDP1MAPTLMNA | |
| SCHEMBL27630962 | 0.85 | CYP19A1 (0.55) | ALDH1A1TSHRTDP1MAPTLMNA | |
| SCHEMBL11427652 | 0.84 | HTT (0.56) | ALDH1A1TSHRTDP1MAPTLMNA | |
| SCHEMBL13788938 | 0.84 | MAPT (0.56) | ALDH1A1TSHRTDP1MAPTLMNA | |
| SCHEMBL9638940 | 0.82 | ALDH1A1 (0.56) | ALDH1A1TDP1MAPTLMNAKMT2A | |
| SCHEMBL16943506 | 0.82 | ALDH1A1 (0.53) | ALDH1A1TSHRTDP1MAPTLMNA | |
| SCHEMBL11820701 | 0.82 | ALDH1A1 (0.51) | ALDH1A1TSHRTDP1MAPTLMNA | |
| SCHEMBL9655337 | 0.82 | MAPT (0.53) | ALDH1A1TSHRTDP1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294792-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294792-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | ALDH1A1 1688/4885TSHR 3594/4885TDP1 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.